Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Lynda Foltz, MD FRCPC, Gian-Matteo Pica, MD, Hacene Zerazhi, Jan Van Droogenbroeck, MD, Sorin Visanica, MD, Enrique Báez de la Fuente, MD, Brian Leber, MD, Antonio Medina de Almeida, MD PhD, Dana Ranta, MD, Mauricio Reyes Cartes, MD, Jean-Jacques Kiladjian, MD PhD, Linda Chrit, PhD, Zhaoyu Yin, PhD, Juliane Morando, MD, Timothy Devos

Blood (2018) 132 (Supplement 1): 1774.

https://doi.org/10.1182/blood-2018-99-111479

Published: 2018

Journal Articles

Can the Autologous Transplant of Hematopoyetic Progenitors be Considered an Effective Alternative to Increase Global Survival in High-Grade Non-Hodgkin Lymphomas?

Alba Nydia Ramirez Lopez, MD, Enrique Baez De La Fuente, MD, Rosa Elva De Leon Cantu, MD, Diego Cruz Contreras, MD, Jose Alfredo Carrizalez Villarreal, MD, Jose Luis Cedillo De La Cerda, Roxana Saldaña Vazquez, MD, Helga Patricia Sorkee Davila, MD, Axel Eduardo Rosas Rodríguez, MD, Severiano Baltazar Arellano, MD, Roberto Hernandez Valdes, MD, Bernardo Lafarga Amao, RESIDENTE, Rosa Lozano, MD, Andrea Terrazas, MD

Blood (2017) 130 (Supplement 1): 5520.

https://doi.org/10.1182/blood.V130.Suppl_1.5520.5520

Published: 2017

Journal Articles

Safety and Efficacy of Ruxolitinib (rux) in an Open-Label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatments Are Available

Timothy Devos, MD, Gian Matteo Pica, MD, Hacene Zerazhi, Jan Van Droogenbroeck, Sorin Visanica, Enrique Báez de la Fuente, Brian Leber, MD, Antonio Medina de Almeida, MD PhD, Dana Ranta, Tomasa Martinez, Jean-Jacques Kiladjian, MD PhD, Linda Chrit, Zhaoyu Yin, Julian Perez Ronco, Lynda Foltz

Blood (2017) 130 (Supplement 1): 2918.

https://doi.org/10.1182/blood.V130.Suppl_1.2918.2918

Published: 2017

Journal Articles

Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post – Polycythemia, Vera Myelofibrosis (PPV – MF), and Post–Essential Thrombocythemia Myelofibrosis (PET – MF)

Pablo Vargas, MD, Roberto Ovilla, MD, Martha Alvarado, MD, Manuel Lopez, MD, Rafael Hurtado Monroy, MD., Juan_Carlos Solis, MD, Alejandro Limon, MD, Gladys Agreda, MD, Salvador Silva, MD, Juan Julio Kassack, MD, Saida Zavala, MD, Carlos Aguilar, MD, Enrique Baez, Esperanza Barrera, MD, Antonio Osuna, MD, Javier Morales, MD, Aquileo Herrera, MD

Blood (2012) 120 (21): 5067.

https://doi.org/10.1182/blood.V120.21.5067.5067

Published: 2012

Journal Articles

Cost-Effectiveness Analysis for Integral Treatment of Chronic Myeloid Leukemia in Chronic Phase at the Instituto Mexicano del Seguro Social (IMSS) Mexico.

Luisa Tenorio, MD, Juan Vargas E, Enrique Baez, MD, Carolina Afanador, MD, Leon Zapata, ChE, Enrique Gomez-Morales, MD

Blood (2006) 108 (11): 4789.

https://doi.org/10.1182/blood.V108.11.4789.4789

Published: 2006

Journal Articles

Is First Line Single Agent Rituximab the Best Treatment for Indolent Non-Hodgkin’s Lymphoma? Update of a Multicentric Study Comparing Rituximab vs CNOP vs Rituximab Plus CNOP.

Silvia Rivas-Vera, MD, Enrique Baez, MD, Pedro Sobrevilla-Calvo, MD, Severiano Baltazar, MD, Francisco Tripp, MD, Jorge Vela, MD, Oscar Garces, MD, Luis Aguilar, MD, Gregorio Ignacio, MD, Jorge Duque, MD, Petty Rodriguez, MD, Gustavo Reyes, MD

Blood (2005) 106 (11): 2431.

https://doi.org/10.1182/blood.V106.11.2431.2431

Published: 2005

Journal Articles

High Incidence of Bcl-2/IgH Rearrangement in Mexican Patients With Follicular Lymphoma and Its Relevance as a Marker for Minimal Residual Disease.

Rosa M. Arana, QFB, Pedro Sobrevilla-Calvo, MD, Silvia Rivas-Vera, MD, Enrique Baez, MD, Severiano Baltazar, MD, Jorge Duque, MD, Ignacio Gregorio, MD, Francisco Tripp, MD, Oscar Garces, MD, Luis Aguilar, MD, Luis Flores, MD

Blood (2005) 106 (11): 4493.

https://doi.org/10.1182/blood.V106.11.4493.4493

Published: 2005

Journal Articles

Clinical Results of a −80°C Simplified Cryo-Preservation Method.

Jose R. Borbolla Escoboza, MD, Manuel A. Lopez-Hernandez, MD, Marcos E. Garza, MD, Enrique Baez, MD, Elvira Trueba, MD, Roberto Hernandez, MD, Jose E. DeDiego-FloresChapa, MD, Severiano Baltazar, MD, Martha Alvarado, MD, Gerardo Villareal, MD, Mauricio C. Gonzalez-Avante, MD, Rosa E. De Leon, MD, Jose L. Cedillo, MD, Jason A. Penniecook, MD, Yara E. Tovar, MD, Maria I. Leon, Cecilia Ramirez-Assad, MD

Blood (2004) 104 (11): 5015.

https://doi.org/10.1182/blood.V104.11.5015.5015

Published: 2004

Journal Articles

Frequency of Genetic Deletions of the Glutathione-S Transferase (Gst) Gene in Mexican Patients with De Novo Acute Leukemia: A Preliminary Report from the “Instituto Tecnologico De Monterrey-Hematology Research Group”.

Blood (2004) 104 (11): 4312.

https://doi.org/10.1182/blood.V104.11.4312.4312

Published: 2004

NARROW

Updated Results from an Open-Label, Multicenter, Expanded Treatment Protocol (ETP) Phase (Ph) 3b Study of Ruxolitinib (RUX) in Patients (Pts) with Polycythemia Vera (PV) Who Were Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatment (Tx) Was Available

Can the Autologous Transplant of Hematopoyetic Progenitors be Considered an Effective Alternative to Increase Global Survival in High-Grade Non-Hodgkin Lymphomas?

Safety and Efficacy of Ruxolitinib (rux) in an Open-Label, Multicenter, Expanded Treatment Protocol in Patients (Pts) with Polycythemia Vera (PV) Who Are Hydroxyurea (HU) Resistant or Intolerant and for Whom No Alternative Treatments Are Available

Compassionate Use Program (CUP) with Ruxolitinib in Mexican Patients with Primary Myelofibrosis (PMF), Post – Polycythemia, Vera Myelofibrosis (PPV – MF), and Post–Essential Thrombocythemia Myelofibrosis (PET – MF)

Cost-Effectiveness Analysis for Integral Treatment of Chronic Myeloid Leukemia in Chronic Phase at the Instituto Mexicano del Seguro Social (IMSS) Mexico.

Is First Line Single Agent Rituximab the Best Treatment for Indolent Non-Hodgkin’s Lymphoma? Update of a Multicentric Study Comparing Rituximab vs CNOP vs Rituximab Plus CNOP.

High Incidence of Bcl-2/IgH Rearrangement in Mexican Patients With Follicular Lymphoma and Its Relevance as a Marker for Minimal Residual Disease.

Clinical Results of a −80°C Simplified Cryo-Preservation Method.

Frequency of Genetic Deletions of the Glutathione-S Transferase (Gst) Gene in Mexican Patients with De Novo Acute Leukemia: A Preliminary Report from the “Instituto Tecnologico De Monterrey-Hematology Research Group”.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only